<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743637</url>
  </required_header>
  <id_info>
    <org_study_id>SDX-0101</org_study_id>
    <nct_id>NCT02743637</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors</brief_title>
  <acronym>SDX-0101</acronym>
  <official_title>A Phase 1 Dose Escalation Study of SDX-7320 to Assess the Safety and Tolerability in Patients With Advanced Refractory or Late-Stage Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SynDevRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SynDevRx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated
      dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage
      solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 dose escalation study to assess the safety and tolerability of
      subcutaneously administered SDX-7320 in patients with advanced refractory or late-stage solid
      tumors.

      Once the MTD has been determined up to 12 patients will be treated at this dose level, to
      further characterize treatment emergent adverse events (TEAEs).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability of SDX-7320 to find the recommended Phase II dose</measure>
    <time_frame>Up to 30 days after last subject enrolled</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>From the screening visit though the end of the last cycle on treatment, an expected average of 16 weeks</time_frame>
    <description>RECIST v1.1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak plasma concentration (Cmax) of active moiety SDX7539</measure>
    <time_frame>Cycle 1, 3, and 6 Day 1: predose, 3, 6, 24, 48, 96 hours; Cycle 2, 4, and 5: predose</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration curve from zero to infinity AUC (0-inf) active moiety SDX7539</measure>
    <time_frame>Cycle 1, 3, and 6 Day 1: predose, 3, 6, 24, 48, 96 hours; Cycle 2, 4, and 5: predose</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Neoplasm</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>SDX-7320</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing dose cohorts, until the maximum tolerated dose (MTD) is determined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SDX-7320</intervention_name>
    <description>SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.</description>
    <arm_group_label>SDX-7320</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have at least one site of radiographically measurable disease.

          -  Eastern Cooperative Oncology Group (ECOG) status ≤1.

          -  Adequate renal and liver functions.

          -  Life expectancy ≥3 months.

        Exclusion Criteria:

          -  Patients that have undergone organ transplant surgery.

          -  The patient has a known history of Hepatitis A, B, or C and is on active anti-viral
             therapy.

          -  History of gastric bypass surgery or banding procedure.

          -  Uncontrolled or refractory hypertension: systolic &gt;180 or diastolic &gt;110, or
             hypotension: systolic &lt;90 or diastolic &lt;50 despite medical treatment.

          -  Participation in any other trial of an investigational agent within 30 days prior to
             first dose of study drug.

          -  The resting 12-lead electrocardiogram obtained during screening shows QTc (Fridericia
             correction) ≥470 ms or has a congenital prolonged QT syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Salomon, MD</last_name>
    <role>Study Director</role>
    <affiliation>SynDevRx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neal Salomon, MD</last_name>
    <phone>(617) 859-6508</phone>
    <email>medicalmonitor@syndevrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer</last_name>
      <phone>480-323-1339</phone>
      <phone_ext>2</phone_ext>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Michael Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nia Harmon</last_name>
      <phone>310-967-8594</phone>
      <email>Nia.Harmon@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AskSarah</last_name>
      <phone>615-339-4214</phone>
    </contact>
    <investigator>
      <last_name>Johanna Bendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://syndevrx.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Oncology</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Phase 1</keyword>
  <keyword>SDX-7320</keyword>
  <keyword>SynDevRx</keyword>
  <keyword>MetAP2</keyword>
  <keyword>Breast</keyword>
  <keyword>Post menopausal</keyword>
  <keyword>Colorectal</keyword>
  <keyword>Pancreatic</keyword>
  <keyword>Ovarian</keyword>
  <keyword>Endometrial</keyword>
  <keyword>Esophageal</keyword>
  <keyword>Lung</keyword>
  <keyword>Renal</keyword>
  <keyword>Prostate</keyword>
  <keyword>Liver</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

